Company Overview

Penumbra, Inc. is a global medical technology company focused on the development and commercialization of innovative devices for the treatment of life-threatening conditions. The company primarily operates in the medical devices and interventional healthcare industries, with a strong emphasis on neurovascular, vascular, and critical care interventions. Penumbra’s products are designed to address conditions such as ischemic stroke, pulmonary embolism, deep vein thrombosis, and other vascular disorders, serving hospitals, physicians, and interventional specialists worldwide.

Founded in 2004, Penumbra has evolved from a neurovascular-focused startup into a diversified interventional device company. Its growth has been driven by internally developed technologies, physician-led innovation, and expanding clinical indications for its platforms. The company is recognized for its aspiration-based thrombectomy technologies and its emphasis on rapid, minimally invasive treatment solutions that improve patient outcomes and procedural efficiency.

Business Operations

Penumbra generates revenue primarily through the sale of single-use medical devices and related systems used in hospital-based interventional procedures. Its core business is organized around major product families within the Neuro and Vascular segments, including the Penumbra System for stroke intervention and the Indigo Aspiration System for peripheral and pulmonary embolism treatment. Revenue is largely recurring, driven by procedure volume and ongoing clinical adoption.

Operations span both domestic and international markets, with manufacturing conducted through a mix of in-house capabilities and qualified external partners. Penumbra controls key proprietary technologies related to aspiration thrombectomy, catheter design, and clot removal systems. The company distributes its products through a direct sales force in major markets and through distributors in select regions, supporting hospitals and specialized treatment centers.

Strategic Position & Investments

Penumbra’s strategic direction centers on expanding its thrombectomy platforms into new indications, improving automation and intelligence within interventional procedures, and increasing penetration in large underserved vascular markets. Growth initiatives include continued clinical research, physician education, and iterative product enhancements such as advanced clot-detection and aspiration efficiency technologies.

The company has pursued selective acquisitions to complement internal development, including the acquisition of Sixense Medical, which strengthened its sensor-enabled catheter capabilities. Penumbra continues to invest in next-generation interventional systems and adjacent clinical areas, positioning itself at the intersection of mechanical thrombectomy, digital-assisted intervention, and minimally invasive care.

Geographic Footprint

Penumbra is headquartered in Alameda, California, and operates across North America, Europe, Asia-Pacific, and parts of Latin America. The United States remains its largest market, accounting for a substantial portion of revenue, supported by a direct commercial organization and close relationships with comprehensive stroke and vascular centers.

Internationally, the company maintains sales, marketing, and operational presence in key countries including Germany, the United Kingdom, Japan, China, and Australia. Its global footprint allows Penumbra to participate in international clinical studies, adapt products to regional regulatory requirements, and capture growth from expanding access to advanced interventional care worldwide.

Leadership & Governance

Penumbra was founded by Adam Elsesser, who has played a central role in shaping its innovation-driven and physician-centric culture. The leadership team emphasizes long-term value creation through disciplined growth, product quality, and patient impact, with governance aligned to public-company standards and regulatory oversight.

Key executives include:

• Adam Elsesser – Chairman and Chief Executive Officer
• Maggie Nixon – Chief Financial Officer
• Sheri Dodd – Chief Operating Officer
• Johanna Flower – Chief Marketing Officer
• J. Steve Runnels – Chief Technology Officer